Project Updates

Credit:Gorodenkoff/Shutterstock.com

Location: Suzhou, China
Project type: GMP Gene Therapy Facility
Size: 8,600m²
Opening: October 2023

Gritgen Therapeutics, a biotechnology company based in China, opened a good manufacturing practice (GMP) facility in Suzhou Industrial Park in Suzhou, China, for commercial production of plasmid and adeno-associated virus (AAV)-based products in October 2023.

Credit:MaaT Pharma

Location: Saint-Quentin-Fallavier, France
Project type: Microbiome Ecosystem Therapies Manufacturing Facility
Construction Started: July 2022
Completed: September 2023

MaaT Pharma, a biotech company based in France, has built a cGMP microbiome ecosystem therapeutics manufacturing facility near Lyon (Saint-Quentin-Fallavier) in France in collaboration with Skyepharma, a French pharmaceutical contract development and manufacturing organisation (CDMO).

Credit:Merck KGaA

Location: Nantong, China
Project type: Reagent Manufacturing Facility
Estimated Investment: €70m
Area: 40,000m²

Germany-based pharmaceutical company Merck will expand its capacity with a new reagent production plant at its existing Nantong site in China. The facility will be utilised for manufacturing of high-purity reagents used in quality control and testing by biopharmaceutical customers.